Eli Lilly to Spend $3.5 Billion on New U.S. Plant for Next-Gen Obesity Drugs
Eli Lilly is doubling down on its push to dominate the fast-growing obesity drug market. The pharmaceutical giant announced plans
Novo Nordisk Walks Away from $10 Billion Biotech Deal — Genius Move or Risky Gamble?
Novo Nordisk Shocks the Market Novo Nordisk, the Danish pharmaceutical giant, stunned investors by pulling out of a $10 billion